Evidence map›Paper›PMID 40381167›Full record

ArticleMolecular neurobiology2025

Eight-Year Longitudinal Study on the Assay Stability of Plasma Amyloid Beta 1-42 Peptide and Total Tau Protein Using Immunomagnetic Reduction.

Mengyao Ji, Mujun Jiang, Qun Yu, Xiaoyun Huang, Yihong Huang, Jun Liu, Wang Liao

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mengyao Ji *Department of Neurology, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Institute of Neuroscience, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Mujun Jiang *Department of Neurology, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Institute of Neuroscience, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Qun Yu *Department of Neurology, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Institute of Neuroscience, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China.
Xiaoyun HuangDepartment of Neurology, The Affiliated Houjie Hospital, Guangdong Medical University, 21 Hetian Road, Dongguan, 523945, People's Republic of China.
Yihong HuangDepartment of Neurology, The Affiliated Houjie Hospital, Guangdong Medical University, 21 Hetian Road, Dongguan, 523945, People's Republic of China.
Jun LiuDepartment of Neurology, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Institute of Neuroscience, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China. liujun@gzhmu.edu.cn.
Wang LiaoDepartment of Neurology, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Institute of Neuroscience, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, China. liaowang@gzhmu.edu.cn.

Funding

Natural Science Foundation of Guangdong province 2024A1515012757Technologies R&D Program of Guangzhou 202206010007Technologies R&D Program of Guangzhou 2023A03J0407the National Natural Science Foundation of China 82101271the National Natural Science Foundation of China 82171178
6 · The paper itself

Abstract

The assay of plasma biomarkers plays a role in the assessment of Alzheimer's disease (AD) and the monitoring of treatments. One of the ultra-sensitive assay technologies is the so-called immunomagnetic reduction (IMR). According to published papers, plasma amyloid β

Indexed as

Amyloid beta-PeptidesImmunomagnetic SeparationPeptide Fragmentstau ProteinsAgedAlzheimer DiseaseBiomarkersFemaleHumansLongitudinal StudiesMaleMiddle AgedProtein StabilityTime FactorsAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersPeptide Fragmentstau ProteinsAmyloid βImmunomagnetic reductionPlasma biomarkersTotal tau

Identifiers

PMID40381167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.